Immunotherapy of Advanced Bladder Cancer – Daniel Petrylak – UroToday
UroToday |
Immunotherapy of Advanced Bladder Cancer – Daniel Petrylak
UroToday Daniel Petrylak, MD presents response rates and anti-tumor activity of checkpoint inhibition therapy in patients with advanced urothelial carcinoma and immunotherapy as initial therapy in cisplatin-ineligible patients and in patients with cisplatin … |
